Decoding Breast Cancer: How Molecular Biology Can Improve Prognosis
"Unlocking the secrets of breast tumors to tailor treatments and improve outcomes for women worldwide."
Breast cancer is a global health challenge, being the most common cancer among women worldwide. Researchers are working tirelessly to understand what triggers the disease, identify key players in its progression, and develop effective, less toxic interventions.
These efforts have led to significant improvements in overall survival, particularly for specific subsets of breast cancer. Treatments and care for breast cancer patients have reached a high standard, but there's still an urgent need to distinguish between tumors requiring aggressive treatment and identify the best therapeutic options tailored to each patient.
Achieving this requires successfully translating the wealth of information clarifying breast cancer biology into clinical practice. Scientists and clinicians must work together, using multidisciplinary approaches to reach this important goal.
The Global Burden of Breast Cancer
Breast cancer was the most frequently diagnosed cancer in women worldwide in 2020, with 2.26 million new cases reported. A 2023 review similarly estimated 2.3 million new cases and more than 685,000 deaths globally. The World Health Organization estimated 694,000 breast cancer deaths in 2024 and reported that it was the most common cancer among women in 164 of 186 countries. In the United States, the reported annual rate was 132.5 new cases and 18.9 deaths per 100,000 women.
From Clinical Factors to Molecular Classification
Breast cancer assessment uses established clinical and pathological information alongside molecular testing and gene-expression classification. Reviews of molecular classification describe both strengths and limitations in using gene-expression patterns to define disease groups. Current literature identifies disease stage among the most important prognostic factors, while also reporting that important prognostic biomarkers and therapeutic targets remain lacking. Molecular subtype can still provide clinically relevant information; for example, basal-like tumors generally have a poorer prognosis than luminal A and luminal B tumors but tend to respond to chemotherapy.
Decades of Progress
Breast cancer research and treatment have advanced substantially over the past five decades, with one review describing significant reductions in cancer mortality. A documented milestone was breast-sparing surgery followed by radiation, associated with Sir Geoffrey on the National Cancer Institute's research timeline. Historical accounts also describe the long development of breast cancer research and treatment. Advances in X-ray technology contributed to the introduction of early detection methods.
Gene Expression Profiles: A New Era of Classification
Traditional methods of classifying breast cancer are evolving thanks to large-scale gene expression profile (GEP) studies. These studies have revealed that breast cancer isn't a single entity but comprises at least four major subtypes: luminal A (LBC-A), luminal B (LBC-B), HER2-positive, and triple-negative/basal-like. This classification is now reinforced by genomic data, demonstrating different recurrent genomic alterations in each subtype.
- Hormone Therapy: Targeted at ER+ and/or PR+ cancers to block hormone-fueled growth.
- Chemotherapy: Traditional cytotoxic drugs to kill rapidly dividing cancer cells.
- Targeted Therapies: Designed to attack specific vulnerabilities in cancer cells, like HER2.
Toward More Precise Prognosis
Recent molecular research continues to refine how breast cancer biology is linked to prognosis and treatment. A 2024 study constructed a prognosis model based on six prognostic-related genes and reported that the model demonstrated predictive value. A 2025 review examined advances in research on breast cancer subtypes and their mechanisms. Early-stage, non-metastatic breast cancer is described in a Nature Reviews Disease Primers article as curable in approximately 70% to 80% of patients.
Limits of Molecular Subtyping
Molecular subtyping is not without unresolved problems. A review of biological subtypes identifies validation, reproducibility, and clinical utility as critical issues. Another analysis emphasizes the need to connect molecular mechanisms with disease prognosis rather than treating classification as an endpoint by itself. These concerns indicate that molecular categories require rigorous confirmation before they can reliably guide clinical decisions.
Different Subtypes, Different Outcomes
Clinical outcomes differ across breast cancer molecular subtypes. Luminal A breast cancer has been reported to have the most favorable clinical outcomes after ionizing irradiation, regardless of whether radiotherapy is used. By contrast, treatment options for unselected patients with triple-negative breast cancer have limited efficacy, and one 2024 source reports that 70% of patients with triple-negative breast cancer do not survive five years. These comparisons show why prognosis cannot be inferred from breast cancer diagnosis alone.
The Future of Breast Cancer Treatment: Personalized and Timely
The key to further improving breast cancer treatment lies in identifying cancers that need aggressive treatment and discovering the most appropriate treatment for each patient. This approach reduces the risk of overtreatment while maximizing the effectiveness of therapy.
Biology and Prognosis Are Intertwined
Hormone receptor-positive tumors have been associated with better prognosis and less aggressive behavior than basal-like and HER2-overexpressed subtypes. This comparison supports the use of molecular characteristics as part of prognostic interpretation. However, an expert discussion questions whether age is an independent prognostic factor or instead reflects underlying tumor biology. Prognosis therefore requires attention to both patient characteristics and the biology of the tumor.
More Individualized Breast Cancer Care
Molecular testing is expected to play an important role in the future of breast cancer care. Expert commentary specifically considers how molecular testing may shape that future. Current treatment research and development are described as moving toward more precise, targeted, and individualized therapies. The direction of the field is therefore toward matching treatment more closely to the molecular characteristics of each cancer.
Socioeconomic Differences Matter
Socioeconomic disparities may contribute to differences in breast cancer tumor biology, stage at diagnosis, and prognosis. A 2026 study was designed to examine these relationships directly. This framing broadens prognostic research beyond molecular measurements alone. It suggests that unequal social conditions may be associated with both the disease observed at diagnosis and the outcomes that follow.
Molecular Findings in Clinical Reality
A study published in Nature Cell Biology examined alternative molecular pathways involved in breast cancer treatment, using work by Heyer and an international team of collaborators. These findings illustrate how molecular targets can identify mechanisms relevant to therapy. Separately, research using a large multicentre real-world database of metastatic breast cancer patients found that molecular subtype strongly affects the occurrence of clinical outcomes. Together, the sources connect laboratory pathway research with the lived clinical reality of metastatic disease.
Studies suggest that breast cancer diagnosed before age 40 requires more accurate classification. Young age at diagnosis is an independent factor associated with higher risk of relapse and death. Differences in the mammary stroma and changes during pregnancy and breastfeeding may contribute to the unique biology of breast cancer in younger women.
Integrating sequencing and gene expression profile studies with high-throughput functional analyses is crucial for identifying genes and pathways that each tumor type is dependent on. Targeting these pathways at the right time, such as during surgery, may significantly impact disease-free and overall survival. Better models that recapitulate the biology of breast cancer in younger women and greater collaboration between clinicians and preclinical researchers are needed.